公开(公告)号：EP3640247A1

公开(公告)日：2020-04-22

申请号：EP18817720.8

申请日：2018-06-14

申请人： Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

发明人： LIU, Shilan ,  LIANG, Guibai ,  WANG, Hongjian ,  ZHANG, Ming ,  CHEN, Shuhui

IPC分类号： C07D401/14 ,  C07D401/04 ,  A61K31/498 ,  A61K31/4709 ,  A61P35/00 ,  A61P29/00

摘要： Provided are a Syk inhibitor and a use method therefor, and in particular, disclosed are quinolinone represented by formula (I) or quinazoline derivatives or pharmaceutically acceptable salts thereof, a preparation method, a pharmaceutical composition, and uses in preparing a medicament for treatment of Syk receptor related diseases.

公开(公告)号：EP3670518A1

公开(公告)日：2020-06-24

申请号：EP18845759.2

申请日：2018-08-17

申请人： Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

发明人： LIU, Shilan ,  WANG, Dahai ,  LIANG, Guibai ,  WANG, Honglin ,  HU, Guoping ,  LI, Jian ,  CHEN, Shuhui

IPC分类号： C07D495/14 ,  A61P37/06

摘要： The present application relates to a crystal of a tricyclic compound, in particular to a crystal of (S)-8-(4,4-difluorocyclohexyl)-8H-thieno[3,4]pyrrolo[1,5-a]imidazole, a preparation method therefor, a crystal composition and a pharmaceutical composition thereof and the use thereof. The X-ray powder diffraction spectrum of the crystal of the compound of formula I in the present application, represented by a 2-θ value, has a diffraction peak at about 11.49°, 15.05°, 20.14°, 21.53° or 21.79°. The crystal of the compound of formula I in the present application has excellent physical properties, high safety and metabolic stability, and has a good inhibitory effect on IDO and a high medicinal value